CAREER ACHIEVEMENT AWARD RECIPIENT




THOMAS O. MCNAMARA, MD



- Undergraduate: St. Johns University, Collegeville, MN. 1962
- Medical School: University of Minnesota. 1966
- Internship Internal Medicine: Moffit Hospital UCSF, San Francisco 1966-67
- Radiology Resident UCSF 1967-68
- US Marine Corps 1968-70 Chief of Radiology
- Diagnostic Radiology: 1970-71
- NeuroRadiology Resident/Fellow 1971-72
- Private Practice Modesto California 1973-1981





ISET

- Moved to Washoe Medical Center in Reno, Nevada 1981-89
- Early 80s: PTA and early lysis was being used and published, and he developed an early interest in interventional techniques and importantly clinical solutions
- He developed a particular interest in thrombolysis and early work being published by Katzen, vanBreda and others with increasing success but significant limitations and side effects
- Began researching the entire field and ultimately exploring the use of urokinase as an alternative



- Because of the clinical experience and scientific work of Dr.
 McNamara, the significant superiority in efficacy and safety of
 Urokinase became proven and the use of catheter directly lysis
 became an essential part of the interventional management of
 PAD and other thrombotic related problems and remains so
 today.
- He was recruited to UCLA in 1989 as Chief of Interventional Radiology where his clinical and scientific commitments and abilities merged to grow that program into great national significance




Inspiration for Innovations?





Drs. Katzen, van Breda. Awoke interest in Lysis, PTA




The joy of performing better procedures.
"relieving pain, & saving limbs.
"helping to develop faster, easier,
safer Rx for an incurable disease.


Countless others: Dotter, Gruentzig, Ring, Castaneda, Motarjeme, Roubin, Walker, Mathias, etc., etc., etc., etc., etc.,

Tom McNamara: Highlights & Fun


1979 (41 yr ago) 1st UK rx with initially hi-dose for acute leg ischemia. SFA & fempop bpg occl. .








Became major Rx for acute leg ischemia



Controversial innovation: Question: Why lysis BTK? It won't dissolve chronic trifurcation occlusions! Answer: Softens clot, gw stays in lumen. Efficacious prior to hydrophilic g.w. . Altered Rx of diabetic CLI in northern NV.



Hot, post revasc.





- As an innovator: participated in development of thrombolytic infusion systems and other parts of the field including catheters, ultrasound enhancement, angioplasty systems, guide wire patents and other innovations to improve patient care
- He developed important areas of interest in Stroke, Limb Salvage, Vascular Malformations and Venous Disease and recently chronic muscular pain
- 2008-Present Professor Emeritus at UCLA



- 2008: Returned to private practice in Carson City Nevada
- 2014: Private Practice in Bishop California Interventional Vascular and Pain Management
- Tom was part of a group of early pioneers to developed and disseminated catheter directed thrombolytic therapy as an integral part of vascular intervention
- Brought clinical practice to the academic setting
- Contributed to the education of many fellows, attendings and practitioners in Vascular Therapy



- Clinician
- Private Practitioner
- Academician
- Innovator
- Teacher
- Significant Contributions to the shaping of Endovascular Therapy
- Congratulations!



CONGRATULATIONS!

CAREER ACHIEVEMENT AWARD RECIPIENT



THOMAS O. MCNAMARA, MD

